Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy
,
Abstract
The plethora of advancements in cancer treatment has resulted in designing unique signatures and personalized therapies, tailored to patient-specific needs, using medications that target specific markers on cancer cells or even retrain the body's immune system. Chimeric Antigen Receptor T-cell, also called as CAR T-cell, is one such approach wherein a patient's cells are modulated to kill the cancer cells. Conventional cancer treatments invite issues like low specificity, increased chances of relapse, or issues with radiotoxicity and tolerance in the case of chemotherapy. Currently, CAR T-cell therapy is under clinical investigation, and different countries are still coming up with their guidelines for the pragmatic application of CAR T. In this review, we present all one needs to know about CAR T-cell therapy, its types, components, side effects, current authorization status in different countries, along with the technology being used in the therapy. We also briefly upon the recent regulations or guidelines released by Europe and the USA, the countries that have actively initiated the CAR T idea. This review aims to provide insight into this targeted therapy, which has the potential to boost cancer research and to help researchers develop more such patient-specific treatments to improve clinical outcomes in cancer.
1. Gils Roex , Tom Feys , Yves Beguin, et al. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics. 2020; 12(2) :194.
2. Yu s, Li A, Liu Q, et al. Chimeric antigen receptor T-cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.
3. E. McGrath and P. Machalik. The Regulatory Framework for CAR T-cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers,” in The EBMT/EHA CAR T-cell Handbook, N. Kröger, J. Gribben, C. Chabannon, I. Yakoub-Agha, and H. Einsele, Eds., Cham (CH): Springer, 2022. Accessed: Apr. 26, 2023. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK584158/.
4. Sterner RC , Sterner RM. CAR T-cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69.
5. Kevin J Curran 1 , Hollie J Pegram, Renier J Brentjens. Chimeric antigen receptors for T-cell immunotherapy: current understanding and future directions. J Gene Med. 2012;14(6):405-15.
6. C Zhang, Liu J, Zhong JF, et al. Engineering CAR T-cells. Biomark Res. 2017;5:22.
7. Mancikova V, Smida M. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2021;22(11):5536.
8. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145-54.
9. A. R. PhD. From the first to the fifth generation of CAR T-cells. ProteoGenix. https://www.proteogenix.science/scientific-corner/CAR T/CAR T-generations/ (accessed Apr. 26, 2023).
10. Autologous vs. allogeneic CAR T: Decisions must be made ‘carefully and deliberately.’ https://www.healio.com/news/hematology-oncology/20201028/autologous-vs-allogeneic-cart-decisions-must-be-made-carefully-and-deliberately (accessed Apr. 26, 2023).
11. National Cancer Institute (NCI), Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing. clinicaltrials.gov, Clinical trial registration NCT03226704, Mar. 2023. Accessed: Apr. 24, 2023. [Online]. Available: https://clinicaltrials.gov/ct2/show/NCT03226704
12. N. Hosseinkhani, Derakhshani A, Kooshkaki O, et al. Immune Checkpoints and CAR T-cells: The Pioneers in Future Cancer Therapies? Int J Mol Sci. 2020;21(21):8305.
13. CAR T-cell Therapy and Its Side Effects. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/CAR T-cell1.html (accessed Apr. 26, 2023).
14. Frontiers | CAR T-cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. https://www.frontiersin.org/articles/10.3389/fimmu.2021.693016/full#B16 (accessed Apr. 26, 2023).
15. Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, et al. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T-cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Front Immunol. 2020; 11: 702.
16. Advantages of CAR T-cell Therapy | Rutgers Cancer Institute of New Jersey. https://www.cinj.org/patient-care/advantages-CAR T-cell-therapy (accessed Apr. 26, 2023).
17. Wolf P, Alzubi J, Gratzke C, et al. The potential of CAR T-cell therapy for prostate cancer. Nat Rev Urol. 2021;18(9): 556-571.
18. Miliotou AN, Papadopoulou LC. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Curr Pharm Biotechnol. 2018; 19(1): 5–18.
19. CAR T-cells: Second-Line Treatment Option for NHL? – NCI https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-CAR T-cells-belinda-transform-zuma7 (accessed Apr. 26, 2023).
20. Wei G, Hu Y, Pu c, et al. CD19 targeted CAR T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Ann Hematol. 2018; 97(5): 781–789.
21. Expanding CAR T-cell Therapy Beyond Cancer | Inside Precision Medicine. https://www.insideprecisionmedicine.com/news-and-features/expanding-CAR T-cell-therapy-beyond-cancer/?gclid=CjwKCAjwzNOaBhAcEiwAD7Tb6Fztzv2jnDk0qVBvbNUhWwEtYq_r4R9Lb2hTrJq-yWobUGDQSl5TRRoCA4AQAvD_BwE# (accessed Apr. 26, 2023).
22. What is CAR T-Cell Therapy? | Advantages, Design, & Toxicity. https://www.allucent.com/resources/blog/what-are-CAR T-cell-therapies (accessed Apr. 26, 2023).
23. W. Yan, Hu H, Tang B. Advances Of Chimeric Antigen Receptor T-cell Therapy In Ovarian Cancer. Onco Targets Ther. 2019; 12: 8015–8022.
24. Zhao L , Cao YJ. Engineered T-cell Therapy for Cancer in the Clinic Front. Immunol 2019 10 Accessed: Apr. 26, 2023. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02250.
25. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf | SpringerLink. https://link.springer.com/article/10.1007/s40259-017-0247-0 (accessed Apr. 26, 2023).
26. Remodeled CAR T-Cell Therapy Causes Fewer Side Effects - NCI https://www.cancer.gov/news-events/cancer-currents-blog/2020/CAR T-cell-therapy-lymphoma-reduced-side-effects (accessed Apr. 26, 2023).
27. C Jérôme. Prise en charge pratique d’une encéphalopathie liée au traitement par cellules CAR T chez l’adulte et l’enfant : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)” Bulletin du Cancer 2020 107, no. 1, p. 12
28. Ali S, Kjeken R, Niederlaender ch, et al. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. Oncologist. 2020; 25(2):e321–e327.
29. Abbasi S, Asghari Totmaj M,Abbasi M, et al. Chimeric antigen receptor T-cells: Novel cell therapy for hematological malignancies. Cancer Med. 2023; 12(7): 7844-7858.
30. Martinez M, Kyung Moon E, et al. CAR T-cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10: 128.
31. Bonifant CL 1 , Jackson HJ 2 , Brentjens RJ, et al. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016:3:16011.
32. “multil.” https://www.lls.org/treatment/types-treatment/immunotherapy/chimeric-antigen-receptor-CAR T-cell-therapy (accessed Apr. 26, 2023).
33. CAR T-cell Therapy for R/R Multiple Myeloma | ABECMA® (idecabtagene vicleucel). https://www.abecma.com/ (accessed Apr. 26, 2023).
34. EMA, Abecma, European Medicines Agency, Jun. 23, 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/abecma (accessed Apr. 26, 2023).
35. Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4): 985–1005.
36. Fala L, Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma. Accessed: Apr. 26, 2023. [Online]
37. Fairfield H, Falank C, Avery L, et al. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016; 1364(1): 32-51.
38. CAR T-cell therapy for Multiple Myeloma | Rho Chi Post. https://rhochistj.org/RhoChiPost/CAR T-cell-therapy-for-multiple-myeloma/ (accessed Apr. 26, 2023).
39. Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc. 2016; 91(1): 101–119.
40. Barlogie B; Shaughnessy J, Tricot G,et al. Treatment of multiple myeloma. Blood. 2004; 103(1): 20–32
41. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma - bluebird bio (NASDAQ:BLUE), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
42. ABECMA® Is a Personalized Immune Cell Therapy That Targets BCMA With a One-Time Infusion1" https://www.abecmahcp.com/mechanism-of-action#:~:text=ABECMA%C2%AE%20Is%20a%20Personalized,With%20a%20One%2DTime%20Infusion&text=Antigen%2Dspecific%20activation%20of%20ABECMA,killing%20of%20BCMA%2Dexpressing%20cells. (accessed May, 2023)
43. Tisagenlecleucel (Kymriah) CAR T-Cell Therapy - Drug Information - Chemocare. https://chemocare.com/chemotherapy/drug-info/tisagenlecleucel.aspx (accessed Apr. 26, 2023).
44. E Roselli, R Faramand, ML Davila. Insight into next-generation CAR therapeutics: designing CAR T-cells to improve clinical outcomes. J Clin Invest. 2021;131(2):e142030.
45. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | NEJM. https://www.nejm.org/doi/full/10.1056/nejmoa1610497 (accessed Apr. 26, 2023).
46. Clinical trials of dual-target CAR T-cells, donor-derived CAR T-cells, and universal CAR T-cells for acute lymphoid leukemia | SpringerLink https://link.springer.com/article/10.1186/s13045-019-0705-x (accessed Apr. 26, 2023).
47. Maude SL, Laetsch TW , Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448.
48. Rosenbaum L. Tragedy, Perseverance, and Chance - The Story of CAR T Therapy. N Engl J Med. 2017; 377(14):1313-1315.
49. R. A. Larson and J. Anastasi. Acute Lymphoblastic Leukemia: Clinical Presentation, Diagnosis, and Classification in Acute Leukemias E. H. Estey, S. H. Faderl, and H. M. Kantarjian, Eds in Hematologic Malignancies. Berlin, Heidelberg: Springer, 2008, pp. 109–118.
50. Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020 Jun 5;13(1):70.
51. Lee DW , Kochenderfer JN 2 , Stetler-Stevenson M, et al. T-cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967): 517–528.
52. T-cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial - The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61403-3/fulltext (accessed Apr. 26, 2023).
53. C. for B. E. and Research, TECARTUS (brexucabtagene autoleucel), FDA Accessed: Apr. 26, 2023. [Online]. Available: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel
54. Brexucabtagene Autoleucel (TecartusTM) : Oncology Times. https://journals.lww.com/oncology-times/Fulltext/2022/08200/Brexucabtagene_Autoleucel__Tecartus__.7.aspx (accessed Apr. 26, 2023).
55. Davila ML , Brentjens RJ. CD19-Targeted CAR T-cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2016; 14(10):802-808.
56. Mian A , Hill BT. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. Expert Opin Biol Ther. 2021; 21(4): 435–441.
57. Romejko-Jarosińska J. CAR T therapy in mantle cell lymphoma: a review of the current literature. Acta Haematol Pol. 2022; 53(3): 166–175.
58. Mantle Cell Lymphoma; Prognosis, Symptoms & Treatment. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/24030-mantle-cell-lymphoma (accessed Apr. 26, 2023).
59. CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma - NCI. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-brexucabtagene-mantle-cell-lymphoma (accessed Apr. 26, 2023).
60. CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphomhttps://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-brexucabtagene-mantle-cell-lymphoma.(accessed June 1, 2023)
61. EMA, Breyanzi. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi (accessed Apr. 26, 2023).
62. Understanding Cancer: Metastasis, Stages of Cancer, and More. https://www.rxlist.com/cancer_101_slideshow_pictures/article.htm (accessed Apr. 26, 2023).
63. What Is Breyanzi® (lisocabtagene maraleucel)?. Breyanzi® (lisocabtagene maraleucel) Patient Site. https://www.breyanzi.com/about (accessed Apr. 26, 2023).
64. S. Bailly et al. Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion pper Hematol. Oncol 2022 40, no. 4, pp. 505–517
65. B-cell Lymphoma: Types, Symptoms & Prognosis. https://my.clevelandclinic.org/health/diseases/22030-b-cell-lymphoma (accessed Apr. 26, 2023).
66. CAR T-cell Therapy Breyanzi® Approved as Relapsed or Refractory Large B-cell Lymphoma Second-Line Therapy in Japan. https://news.bms.com/news/details/2022/CAR T-Cell-Therapy-Breyanzi-Approved-as-Relapsed-or-Refractory-Large-B-cell-Lymphoma-Second-Line-Therapy-in-Japan/default.aspx (accessed Apr. 26, 2023).
67. B Coiffier, C Sarkozy. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program 2016 16(1), pp- 366-378
68. S. S. Neelapu et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma N. Engl. J. Med 2017 377, no. 26, pp. 2531–2544
69. Yescarta CAR T-cell therapy for non-Hodgkin lymphoma patients. https://www.yescarta.com/ (accessed Apr. 26, 2023).
70. Yescarta: Cost, Uses, Side Effects, Dosage, and More.https://www.healthline.com/health/drugs/yescarta#what-to-consider (accessed Apr. 26, 2023).
71. Luminari S, Bellei M, Biasoli I, et al. Follicular lymphoma - treatment and prognostic factors. Rev Bras Hematol Hemoter. 2012 34(1):54-9
72. Kase AM, Kharfan-Dabaja MA, Donaldson A, et al. Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR T. Clin Case Rep. 2022; 10(4):e05572.
73. CAR T has ‘fundamentally changed’ outcomes in follicular lymphoma. https://www.healio.com/news/hematology-oncology/20221004/cart-has-fundamentally-changed-outcomes-in-follicular-lymphoma (accessed Apr. 26, 2023).
74. Follicular Lymphoma: Stages, Symptoms, Treatment & Prognosis Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22606-follicular-lymphoma (accessed Apr. 26, 2023).
75. Patel K, Chotai Np. Documentation and Records: Harmonized GMP Requirements. J Young Pharm. 2011;3(2):138-50
76. Shah NN, Fry TJ. Mechanisms of resistance to CAR T-cell therapy. Nat Rev Clin Oncol. 2019; 16(6): 372-385.
77. C. for B. E. and Research, “Considerations for the Development of Chimeric Antigen Receptor (CAR) T-cell Products,” U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-CAR T-cell-products (accessed Apr. 26, 2023).
78. Lu J, Xu L, Wei W, et al. Advanced therapy medicinal products in China: Regulation and development. MedComm(2020). 2013; 4(3):e251.
79. Locke FL , Davila ML. Regulatory challenges and considerations for the clinical application of CAR T-cell anti-cancer therapy. Expert Opin Biol Ther. 2017; 17(6): 659–661.
80. A unique hub‐and‐spoke model to optimize patient management in lymphoma using novel CAR‐T-cell therapy in Southeast and South Asia - Wei Inng Lim - 2022 - Hematological Oncology - Wiley Online Library. https://onlinelibrary.wiley.com/doi/10.1002/hon.3065 (accessed Apr. 26, 2023).
81. Availability of CAR T-cell therapy: list of all countries. https://www.susupport.com/knowledge/cell-gene-therapy/which-countries-cell-therapy-available (accessed Apr. 26, 2023).
82. Wang X , L Popplewell L , Wagner JR, et al. Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL Blood. 2016; 127(24): 2980–2990.
83. Mock U, Nickolay L, Philip B, et al. Automated manufacturing of chimeric antigen receptor T-cells for adoptive immunotherapy using CliniMACS Prodigy. Cytotherapy. 2016; 18(8):1002–1011.
84. Ghassemi S, Nunez-Cruz S, O'Connor RS, et al. Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T-cells. Cancer Immunol Res. 2018; 6(9): 1100–1109.
85. Zhang W, Jordan KR, Schulte B, et al. Characterization of clinical grade CD19 chimeric antigen receptor T-cells produced using automated CliniMACS prodigy system. Drug Des Devel Ther. 2018; 12: 3343–3356.
86. Hort S, Herbst L, Bäckel N, et al. Toward Rapid, Widely Available Autologous CAR T-cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital. Front Med (Lausanne). 2022:9:913287.
87. Schork NJ. Artificial Intelligence and Personalized Medicine. Cancer Treat Res. 2019; 178: 265-283.
88. Frontiers | Toward Rapid, Widely Available Autologous CAR T-cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital https://www.frontiersin.org/articles/10.3389/fmed.2022.913287/full#B6 (accessed Apr. 26, 2023).
89. Mehrian M, Lambrechts T, Marechal M, et al. Predicting in vitro human mesenchymal stromal cell expansion based on individual donor characteristics using machine learning. Cytotherapy. 2020; 22(2): 82–90.
90. Li S, Todor A, Luo R. Blood transcriptomics and metabolomics for personalized medicine. Comput Struct Biotechnol J. 2015; 14: 1–7.
91. Lock D , Monjezi R , Brandes C. Automated, scaled, transposon-based production of CAR T-cells. J Immunother Cancer. 2022; 10(9): e005189.
92. K. Aleksandrova et al. Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T-cells Manufactured Using the Automated CliniMACS Prodigy® Platform Transfus. Med. Hemotherapy Off. Organ Dtsch. Ges. Transfusionsmedizin Immunhamatologie 2019 46, no. 1, pp. 47–54.
93. Potential solutions for manufacture of CAR T-cells in cancer immunotherapy | Nature Communications. https://www.nature.com/articles/s41467-022-32866-0#ref-CR15 (accessed Apr. 26, 2023).
94. Levine BL, Miskin J, Wonnacott K, et al. Global Manufacturing of CAR T-cell Therapy. Mol Ther Methods Clin Dev. 2016; 4: 92-101.
2. Yu s, Li A, Liu Q, et al. Chimeric antigen receptor T-cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.
3. E. McGrath and P. Machalik. The Regulatory Framework for CAR T-cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers,” in The EBMT/EHA CAR T-cell Handbook, N. Kröger, J. Gribben, C. Chabannon, I. Yakoub-Agha, and H. Einsele, Eds., Cham (CH): Springer, 2022. Accessed: Apr. 26, 2023. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK584158/.
4. Sterner RC , Sterner RM. CAR T-cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69.
5. Kevin J Curran 1 , Hollie J Pegram, Renier J Brentjens. Chimeric antigen receptors for T-cell immunotherapy: current understanding and future directions. J Gene Med. 2012;14(6):405-15.
6. C Zhang, Liu J, Zhong JF, et al. Engineering CAR T-cells. Biomark Res. 2017;5:22.
7. Mancikova V, Smida M. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. Int J Mol Sci. 2021;22(11):5536.
8. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145-54.
9. A. R. PhD. From the first to the fifth generation of CAR T-cells. ProteoGenix. https://www.proteogenix.science/scientific-corner/CAR T/CAR T-generations/ (accessed Apr. 26, 2023).
10. Autologous vs. allogeneic CAR T: Decisions must be made ‘carefully and deliberately.’ https://www.healio.com/news/hematology-oncology/20201028/autologous-vs-allogeneic-cart-decisions-must-be-made-carefully-and-deliberately (accessed Apr. 26, 2023).
11. National Cancer Institute (NCI), Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing. clinicaltrials.gov, Clinical trial registration NCT03226704, Mar. 2023. Accessed: Apr. 24, 2023. [Online]. Available: https://clinicaltrials.gov/ct2/show/NCT03226704
12. N. Hosseinkhani, Derakhshani A, Kooshkaki O, et al. Immune Checkpoints and CAR T-cells: The Pioneers in Future Cancer Therapies? Int J Mol Sci. 2020;21(21):8305.
13. CAR T-cell Therapy and Its Side Effects. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/CAR T-cell1.html (accessed Apr. 26, 2023).
14. Frontiers | CAR T-cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. https://www.frontiersin.org/articles/10.3389/fimmu.2021.693016/full#B16 (accessed Apr. 26, 2023).
15. Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, et al. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T-cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Front Immunol. 2020; 11: 702.
16. Advantages of CAR T-cell Therapy | Rutgers Cancer Institute of New Jersey. https://www.cinj.org/patient-care/advantages-CAR T-cell-therapy (accessed Apr. 26, 2023).
17. Wolf P, Alzubi J, Gratzke C, et al. The potential of CAR T-cell therapy for prostate cancer. Nat Rev Urol. 2021;18(9): 556-571.
18. Miliotou AN, Papadopoulou LC. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Curr Pharm Biotechnol. 2018; 19(1): 5–18.
19. CAR T-cells: Second-Line Treatment Option for NHL? – NCI https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-CAR T-cells-belinda-transform-zuma7 (accessed Apr. 26, 2023).
20. Wei G, Hu Y, Pu c, et al. CD19 targeted CAR T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Ann Hematol. 2018; 97(5): 781–789.
21. Expanding CAR T-cell Therapy Beyond Cancer | Inside Precision Medicine. https://www.insideprecisionmedicine.com/news-and-features/expanding-CAR T-cell-therapy-beyond-cancer/?gclid=CjwKCAjwzNOaBhAcEiwAD7Tb6Fztzv2jnDk0qVBvbNUhWwEtYq_r4R9Lb2hTrJq-yWobUGDQSl5TRRoCA4AQAvD_BwE# (accessed Apr. 26, 2023).
22. What is CAR T-Cell Therapy? | Advantages, Design, & Toxicity. https://www.allucent.com/resources/blog/what-are-CAR T-cell-therapies (accessed Apr. 26, 2023).
23. W. Yan, Hu H, Tang B. Advances Of Chimeric Antigen Receptor T-cell Therapy In Ovarian Cancer. Onco Targets Ther. 2019; 12: 8015–8022.
24. Zhao L , Cao YJ. Engineered T-cell Therapy for Cancer in the Clinic Front. Immunol 2019 10 Accessed: Apr. 26, 2023. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02250.
25. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf | SpringerLink. https://link.springer.com/article/10.1007/s40259-017-0247-0 (accessed Apr. 26, 2023).
26. Remodeled CAR T-Cell Therapy Causes Fewer Side Effects - NCI https://www.cancer.gov/news-events/cancer-currents-blog/2020/CAR T-cell-therapy-lymphoma-reduced-side-effects (accessed Apr. 26, 2023).
27. C Jérôme. Prise en charge pratique d’une encéphalopathie liée au traitement par cellules CAR T chez l’adulte et l’enfant : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)” Bulletin du Cancer 2020 107, no. 1, p. 12
28. Ali S, Kjeken R, Niederlaender ch, et al. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. Oncologist. 2020; 25(2):e321–e327.
29. Abbasi S, Asghari Totmaj M,Abbasi M, et al. Chimeric antigen receptor T-cells: Novel cell therapy for hematological malignancies. Cancer Med. 2023; 12(7): 7844-7858.
30. Martinez M, Kyung Moon E, et al. CAR T-cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10: 128.
31. Bonifant CL 1 , Jackson HJ 2 , Brentjens RJ, et al. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016:3:16011.
32. “multil.” https://www.lls.org/treatment/types-treatment/immunotherapy/chimeric-antigen-receptor-CAR T-cell-therapy (accessed Apr. 26, 2023).
33. CAR T-cell Therapy for R/R Multiple Myeloma | ABECMA® (idecabtagene vicleucel). https://www.abecma.com/ (accessed Apr. 26, 2023).
34. EMA, Abecma, European Medicines Agency, Jun. 23, 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/abecma (accessed Apr. 26, 2023).
35. Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4): 985–1005.
36. Fala L, Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma. Accessed: Apr. 26, 2023. [Online]
37. Fairfield H, Falank C, Avery L, et al. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016; 1364(1): 32-51.
38. CAR T-cell therapy for Multiple Myeloma | Rho Chi Post. https://rhochistj.org/RhoChiPost/CAR T-cell-therapy-for-multiple-myeloma/ (accessed Apr. 26, 2023).
39. Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc. 2016; 91(1): 101–119.
40. Barlogie B; Shaughnessy J, Tricot G,et al. Treatment of multiple myeloma. Blood. 2004; 103(1): 20–32
41. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma - bluebird bio (NASDAQ:BLUE), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
42. ABECMA® Is a Personalized Immune Cell Therapy That Targets BCMA With a One-Time Infusion1" https://www.abecmahcp.com/mechanism-of-action#:~:text=ABECMA%C2%AE%20Is%20a%20Personalized,With%20a%20One%2DTime%20Infusion&text=Antigen%2Dspecific%20activation%20of%20ABECMA,killing%20of%20BCMA%2Dexpressing%20cells. (accessed May, 2023)
43. Tisagenlecleucel (Kymriah) CAR T-Cell Therapy - Drug Information - Chemocare. https://chemocare.com/chemotherapy/drug-info/tisagenlecleucel.aspx (accessed Apr. 26, 2023).
44. E Roselli, R Faramand, ML Davila. Insight into next-generation CAR therapeutics: designing CAR T-cells to improve clinical outcomes. J Clin Invest. 2021;131(2):e142030.
45. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | NEJM. https://www.nejm.org/doi/full/10.1056/nejmoa1610497 (accessed Apr. 26, 2023).
46. Clinical trials of dual-target CAR T-cells, donor-derived CAR T-cells, and universal CAR T-cells for acute lymphoid leukemia | SpringerLink https://link.springer.com/article/10.1186/s13045-019-0705-x (accessed Apr. 26, 2023).
47. Maude SL, Laetsch TW , Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448.
48. Rosenbaum L. Tragedy, Perseverance, and Chance - The Story of CAR T Therapy. N Engl J Med. 2017; 377(14):1313-1315.
49. R. A. Larson and J. Anastasi. Acute Lymphoblastic Leukemia: Clinical Presentation, Diagnosis, and Classification in Acute Leukemias E. H. Estey, S. H. Faderl, and H. M. Kantarjian, Eds in Hematologic Malignancies. Berlin, Heidelberg: Springer, 2008, pp. 109–118.
50. Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020 Jun 5;13(1):70.
51. Lee DW , Kochenderfer JN 2 , Stetler-Stevenson M, et al. T-cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967): 517–528.
52. T-cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial - The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61403-3/fulltext (accessed Apr. 26, 2023).
53. C. for B. E. and Research, TECARTUS (brexucabtagene autoleucel), FDA Accessed: Apr. 26, 2023. [Online]. Available: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel
54. Brexucabtagene Autoleucel (TecartusTM) : Oncology Times. https://journals.lww.com/oncology-times/Fulltext/2022/08200/Brexucabtagene_Autoleucel__Tecartus__.7.aspx (accessed Apr. 26, 2023).
55. Davila ML , Brentjens RJ. CD19-Targeted CAR T-cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2016; 14(10):802-808.
56. Mian A , Hill BT. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. Expert Opin Biol Ther. 2021; 21(4): 435–441.
57. Romejko-Jarosińska J. CAR T therapy in mantle cell lymphoma: a review of the current literature. Acta Haematol Pol. 2022; 53(3): 166–175.
58. Mantle Cell Lymphoma; Prognosis, Symptoms & Treatment. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/24030-mantle-cell-lymphoma (accessed Apr. 26, 2023).
59. CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma - NCI. https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-brexucabtagene-mantle-cell-lymphoma (accessed Apr. 26, 2023).
60. CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphomhttps://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-brexucabtagene-mantle-cell-lymphoma.(accessed June 1, 2023)
61. EMA, Breyanzi. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi (accessed Apr. 26, 2023).
62. Understanding Cancer: Metastasis, Stages of Cancer, and More. https://www.rxlist.com/cancer_101_slideshow_pictures/article.htm (accessed Apr. 26, 2023).
63. What Is Breyanzi® (lisocabtagene maraleucel)?. Breyanzi® (lisocabtagene maraleucel) Patient Site. https://www.breyanzi.com/about (accessed Apr. 26, 2023).
64. S. Bailly et al. Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion pper Hematol. Oncol 2022 40, no. 4, pp. 505–517
65. B-cell Lymphoma: Types, Symptoms & Prognosis. https://my.clevelandclinic.org/health/diseases/22030-b-cell-lymphoma (accessed Apr. 26, 2023).
66. CAR T-cell Therapy Breyanzi® Approved as Relapsed or Refractory Large B-cell Lymphoma Second-Line Therapy in Japan. https://news.bms.com/news/details/2022/CAR T-Cell-Therapy-Breyanzi-Approved-as-Relapsed-or-Refractory-Large-B-cell-Lymphoma-Second-Line-Therapy-in-Japan/default.aspx (accessed Apr. 26, 2023).
67. B Coiffier, C Sarkozy. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program 2016 16(1), pp- 366-378
68. S. S. Neelapu et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma N. Engl. J. Med 2017 377, no. 26, pp. 2531–2544
69. Yescarta CAR T-cell therapy for non-Hodgkin lymphoma patients. https://www.yescarta.com/ (accessed Apr. 26, 2023).
70. Yescarta: Cost, Uses, Side Effects, Dosage, and More.https://www.healthline.com/health/drugs/yescarta#what-to-consider (accessed Apr. 26, 2023).
71. Luminari S, Bellei M, Biasoli I, et al. Follicular lymphoma - treatment and prognostic factors. Rev Bras Hematol Hemoter. 2012 34(1):54-9
72. Kase AM, Kharfan-Dabaja MA, Donaldson A, et al. Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR T. Clin Case Rep. 2022; 10(4):e05572.
73. CAR T has ‘fundamentally changed’ outcomes in follicular lymphoma. https://www.healio.com/news/hematology-oncology/20221004/cart-has-fundamentally-changed-outcomes-in-follicular-lymphoma (accessed Apr. 26, 2023).
74. Follicular Lymphoma: Stages, Symptoms, Treatment & Prognosis Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22606-follicular-lymphoma (accessed Apr. 26, 2023).
75. Patel K, Chotai Np. Documentation and Records: Harmonized GMP Requirements. J Young Pharm. 2011;3(2):138-50
76. Shah NN, Fry TJ. Mechanisms of resistance to CAR T-cell therapy. Nat Rev Clin Oncol. 2019; 16(6): 372-385.
77. C. for B. E. and Research, “Considerations for the Development of Chimeric Antigen Receptor (CAR) T-cell Products,” U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-CAR T-cell-products (accessed Apr. 26, 2023).
78. Lu J, Xu L, Wei W, et al. Advanced therapy medicinal products in China: Regulation and development. MedComm(2020). 2013; 4(3):e251.
79. Locke FL , Davila ML. Regulatory challenges and considerations for the clinical application of CAR T-cell anti-cancer therapy. Expert Opin Biol Ther. 2017; 17(6): 659–661.
80. A unique hub‐and‐spoke model to optimize patient management in lymphoma using novel CAR‐T-cell therapy in Southeast and South Asia - Wei Inng Lim - 2022 - Hematological Oncology - Wiley Online Library. https://onlinelibrary.wiley.com/doi/10.1002/hon.3065 (accessed Apr. 26, 2023).
81. Availability of CAR T-cell therapy: list of all countries. https://www.susupport.com/knowledge/cell-gene-therapy/which-countries-cell-therapy-available (accessed Apr. 26, 2023).
82. Wang X , L Popplewell L , Wagner JR, et al. Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL Blood. 2016; 127(24): 2980–2990.
83. Mock U, Nickolay L, Philip B, et al. Automated manufacturing of chimeric antigen receptor T-cells for adoptive immunotherapy using CliniMACS Prodigy. Cytotherapy. 2016; 18(8):1002–1011.
84. Ghassemi S, Nunez-Cruz S, O'Connor RS, et al. Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T-cells. Cancer Immunol Res. 2018; 6(9): 1100–1109.
85. Zhang W, Jordan KR, Schulte B, et al. Characterization of clinical grade CD19 chimeric antigen receptor T-cells produced using automated CliniMACS prodigy system. Drug Des Devel Ther. 2018; 12: 3343–3356.
86. Hort S, Herbst L, Bäckel N, et al. Toward Rapid, Widely Available Autologous CAR T-cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital. Front Med (Lausanne). 2022:9:913287.
87. Schork NJ. Artificial Intelligence and Personalized Medicine. Cancer Treat Res. 2019; 178: 265-283.
88. Frontiers | Toward Rapid, Widely Available Autologous CAR T-cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital https://www.frontiersin.org/articles/10.3389/fmed.2022.913287/full#B6 (accessed Apr. 26, 2023).
89. Mehrian M, Lambrechts T, Marechal M, et al. Predicting in vitro human mesenchymal stromal cell expansion based on individual donor characteristics using machine learning. Cytotherapy. 2020; 22(2): 82–90.
90. Li S, Todor A, Luo R. Blood transcriptomics and metabolomics for personalized medicine. Comput Struct Biotechnol J. 2015; 14: 1–7.
91. Lock D , Monjezi R , Brandes C. Automated, scaled, transposon-based production of CAR T-cells. J Immunother Cancer. 2022; 10(9): e005189.
92. K. Aleksandrova et al. Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T-cells Manufactured Using the Automated CliniMACS Prodigy® Platform Transfus. Med. Hemotherapy Off. Organ Dtsch. Ges. Transfusionsmedizin Immunhamatologie 2019 46, no. 1, pp. 47–54.
93. Potential solutions for manufacture of CAR T-cells in cancer immunotherapy | Nature Communications. https://www.nature.com/articles/s41467-022-32866-0#ref-CR15 (accessed Apr. 26, 2023).
94. Levine BL, Miskin J, Wonnacott K, et al. Global Manufacturing of CAR T-cell Therapy. Mol Ther Methods Clin Dev. 2016; 4: 92-101.
| Files | ||
| Issue | Vol 19 No 2 (2025) | |
| Section | Review Article(s) | |
| Keywords | ||
| Immunotherapy; CAR T-cell therapy; Cancer; Immunology | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Vinoo S, Jaiswal D, Mehta P, Battu A, Majumdar A. Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy. Int J Hematol Oncol Stem Cell Res. 2025;19(2):177-188.
